MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer
Open accessAbstract
We have established a novel ascites tumour model (MDA435/LCC6) from the oestrogen receptor-negative, invasive and metastatic MDA-MB-435 human breast cancer cell line. MDA435/LCC6 cells grow as both malignant ascites and solid tumours in vivo in nude mice and nude rats, with a tumour incidence of approximately 100%. Untreated mice develop ascites following i.p. inoculation of 1 x 10(6) cells and have a reproducible life span of approximately 30 days, with all animals dying within a 48 h period. The in vivo response of MDA435/LCC6 ascites to several cytotoxic drugs, including doxorubicin, etoposide (VP-16), BCNU and mitomycin C, closely reflects the activity of these single agents in previously untreated breast cancer patients. MDA435/LCC6 cells also retain the anchorage-dependent and anchorage-independent in vitro growth properties of the parental MDA-MB-435 cells, and can be used in standard in vitro drug screening assays. The drug resistance pattern of the MDA435/LCC6 cells suggests that they may have few active endogenous drug resistance mechanisms. To generate a model for the screening of MDR1-reversing agents, MDA435/LCC6 were transduced with a retroviral vector directing the constitutive expression of the MDR1 cDNA, producing a cell line with a classical MDR1 resistance pattern (MDA435/LCC6MDR1). THese ascites models may be a viable alternative to the murine leukaemia ascites (L1210, P388) and, in conjunction with other breast cancer cell lines, facilitate the in vitro and in vivo screening of new cytotoxic drugs and drug combinations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Polymeric micelles based on amphiphilic block copolymers of poly(2-alkyl-2-oxazoline)s, specifically P(MeOx-BuOx-MeOx) triblock copolymer, are a novel drug carrier system that stands apart in drug loading.
“One novel drug carrier system that stands apart from the others in that regard is polymeric micelles [11], based on amphiphilic block copolymers of poly(2-alkyl-2-oxazoline)s and specifically the poly[(2-methyl-2-oxazoline)-b-(2-butyl-2-oxazoline)-b-(2-methyl-2-oxazoline)] (P(MeOx-BuOx-MeOx) triblock copolymer [12].”
From Co-delivery of Paclitaxel and Cisplatin in Poly(2-oxazoline) Polymeric Micelles: Implications for Drug Loading, Release, Pharmacokinetics and Outcome of Ovarian and Breast Cancer Treatments (2019) · cites this paper as [11]
The Results and Discussion passages describe MDA435/LCC6 breast-cancer ascites models and drug resistance, not the P(MeOx-BuOx-MeOx) triblock copolymer cited as [12]. Searches for the copolymer’s name and for polymeric micelles and drug carriers found no passage addressing it. Page numbers were not available in our copy’s retrieved passages. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 43 · Cited by 102
- Authors
- Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M., & Clarke, R.
- Affiliations
- Georgetown University (US)
- National Institutes of Health (US)
- Venue
- British Journal of Cancer
- Published
- 1996-01
- Volume
- 73
- Issue
- 2
- Pages
- 154-161
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2074305
- OpenAlex
- W2027344275
- Cited by
- 102
- References
- 43
- Citations by year
- 2025: 1 · 2023: 1 · 2019: 2 · 2018: 2 · 2016: 1 · 2015: 7 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- British Journal of Cancer (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (UO1CA-51908, U01CA051908, R01CA058022, P50CA058185)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- MDA-MB-435, breast cancer, estrogen receptor-negative breast cancer, MDR1, multidrug resistance, drug resistance testing, retroviral transduction, doxorubicin, etoposide, BCNU, mitomycin C, anchorage-independent growth, nude mice, nude rats
- MeSH terms
- Adult, Animals, Antineoplastic Agents, Ascites, Breast Neoplasms, Disease Models, Animal, Drug Screening Assays, Antitumor, Female, Humans, Mice, Nude, Rats, Nude, Receptors, Estrogen, Tumor Cells, Cultured, Carcinoma, Medullary, Drug Resistance, Multiple, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
